WO2011061613A1 - Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib - Google Patents
Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib Download PDFInfo
- Publication number
- WO2011061613A1 WO2011061613A1 PCT/IB2010/002967 IB2010002967W WO2011061613A1 WO 2011061613 A1 WO2011061613 A1 WO 2011061613A1 IB 2010002967 W IB2010002967 W IB 2010002967W WO 2011061613 A1 WO2011061613 A1 WO 2011061613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sunitinib
- malic acid
- acid salt
- crystalline form
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- U.S. Patent Application Nos. 2003/0069298 and 2007/0191458 describe the preparation of crystalline Forms I and II of L-malic acid salt of sunitinib.
- crystalline Form I of L-malic acid salt of sunitinib is prepared by slurrying a poorly crystalline or crystalline Form II of L-malic acid salt of sunitinib in acetonitrile.
- Crystalline Form II of the L-malic acid salt of sunitinib is prepared by dissolving crystal Form I of L-malic acid salt of sunitinib in tetrahydrofuran and water and allowing the solvent to evaporate overnight.
- step b) removing the solvent from the solution obtained in step a) by spray drying; and c) collecting crystalline Form ⁇ of L-malic acid salt of sunitinib from the spray dryer.
- the XRPD of the samples were determined by using Panalytical X'Pert Pro X-Ray
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to stable crystalline Form II of L-malic acid salt of sunitinib and its preparation.
Description
PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM II OF
L-MALIC ACID SALT OF SUNITINIB
Field of the Invention
The present invention relates to stable crystalline Form Π of a L-malic acid salt of sunitinib and a process for the preparation thereof.
Background of the Invention
Sunitinib is chemically described as N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro- l,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-lH-pyrrole-3-carboxarnide as represented by Formula I.
FORMULA I
Sunitinib is an oral multi-kinase inhibitor and useful for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Sunitinib is
commercially available as the L-malate salt, which is described chemically as butanedioic acid, hydroxy-, (2S)-, compound with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-l,2- dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-lH-pyrrole-3-carboxamide (1: 1).
U.S. Patent Application Nos. 2003/0069298 and 2007/0191458 describe the preparation of crystalline Forms I and II of L-malic acid salt of sunitinib. According to these applications, crystalline Form I of L-malic acid salt of sunitinib is prepared by slurrying a poorly crystalline or crystalline Form II of L-malic acid salt of sunitinib in acetonitrile. Crystalline Form II of the L-malic acid salt of sunitinib is prepared by
dissolving crystal Form I of L-malic acid salt of sunitinib in tetrahydrofuran and water and allowing the solvent to evaporate overnight.
WO 2009/067686 describes processes for preparing crystalline Forms of racemic sunitinib malate, sunitinib hemi-L-malate and compositions containing sunitinib base and L- or racemic malic acid.
WO 2009/104021 describes processes for preparing crystalline Forms ΙΠ and IV of sunitinib L-malate.
WO 2009/104021 describes that Form II of sunitinib L-malate is hygroscopic, thermodynamically unstable and appears to readily convert to Form I.
Summary of the Invention
In one general aspect, the present invention provides for a stable crystalline Form II of L-malic acid salt of sunitinib.
Embodiments of this aspect may include one or more of the following aspects. For example, the stable crystalline Form II of L-malic acid salt does not convert into any other solid form on storage of about 20 days or more. The stable crystalline Form Π of L-malic acid salt absorbs moisture to a level of not more than about 2%.
In another general aspect, the present invention provides for a process for the preparation of crystalline Form II of L-malic acid salt of sunitinib. The process includes: a) charging a solution of L-malic acid salt of sunitinib in a solvent to a spray
dryer;
b) removing the solvent from the solution obtained in step a) by spray drying; and c) collecting crystalline Form Π of L-malic acid salt of sunitinib from the spray dryer.
Embodiments of this aspect may include one or more of the following features. For example, the solvent may be water, an alkanol, such as methanol, or a mixture thereof.
Brief Description of the Drawings
Figure 1 depicts the X-ray powder diffraction pattern (XRPD) of the stable crystalline Form II of L-malic acid salt of sunitinib.
Figure 1A provides table of values for the XRPD pattern depicted in Figure 1.
Figure 2 depicts the X-ray powder diffraction pattern (XRPD) of the stable crystalline Form Π of L-malic acid salt of sunitinib after the storage of 24 days.
Figure 2A provides table of values for the XRPD pattern depicted in Figure 2.
Detailed Description of the Invention
The term "L-malic acid salt of sunitinib" includes a combination of sunitinib and . L-malic acid in any molar ratio between about 1 :0.75 and about 1: 1.5.
The term "charging", according to the present invention, includes loading, filling, introducing, pouring, infusing and/or adding.
The term "collecting", according to the present invention, includes unloading, gathering and/or scaling.
The present invention provides a stable crystalline Form II of L-malic acid salt of sunitinib. The stable crystalline Form II of L-malic acid salt of sunitinib has an XRPD pattern wherein the characteristic 2Θ values are obtained substantially at 3.08 ± 0.2, 6.14 + 0.2, 7.77 + 0.2, 9.23 + 0.2, 12.24 + 0.2, 14.55 + 0.2, 22.58 ± 0.2, 24.08 + 0.2 and 27.03 + 0.2 degree 2Θ. The stable crystalline Form II of L-malic acid salt does not convert into any other solid form upon storage for about 20 days or more. The stable crystalline Form II of L-malic acid salt absorbs moisture to a level of not more than about 2%, for example, not more than between about 1% to about 1.5%.
The present invention also provides for a process for the preparation of crystalline
Form II of L-malic acid salt of sunitinib. The process includes:
a) charging a solution of L-malic acid salt of sunitinib in a solvent to a spray dryer;
b) removing the solvent from the solution obtained in step a) by spray drying; and c) collecting crystalline Form Π of L-malic acid salt of sunitinib from the spray dryer.
L-Malic acid salt of sunitinib existing in any solid form prepared by any method known in literature, for example, U.S. Patent Nos. 6,573,293 and 7,125,905; and WO
2004/012776 may be used for preparing the solution of L-malic acid salt of sunitinib in a solvent.
The solution of L-malic acid salt of sunitinib in a solvent may also be prepared by dissolving sunitinib base and L-malic acid in a solvent. The solvent may be water or an alkanol, for example, methanol, or a mixture thereof. The solution may optionally be filtered prior to charging to the spray dryer. The inlet and outlet temperatures, feed rate, and atomizer type may be adjusted to optimize output and particle size. The air inlet temperature may be controlled from about 60°C to about 150°C, for example, about 100°C to about 140°C. The outlet temperature may be controlled from about 30°C to about 80°C, for example, about 50°C to about 70°C. An inert gas, for example, nitrogen gas can be used as a carrier gas. After spray drying, the crystalline Form II of L-malic acid salt of sunitinib is collected from the spray dryer and optionally further dried under vacuum to remove the residual solvents. The crystalline Form Π of L-malic acid salt of sunitinib so obtained is stable and has substantially the same XRPD pattern as depicted in Figure 1.
The XRPD of the samples were determined by using Panalytical X'Pert Pro X-Ray
Powder Diffractometer in the range 3-40 degree 2 theta and under tube voltage and current of 45 Kv and 40 mA respectively. Copper radiation of wavelength 1.54 angstrom and Xceletor detector was used.
While the present invention has been described in terms of its specific
embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLE
Example 1: Preparation of Stable Crystalline Form Ii of L-Malic Acid Salt of Sunitinib
L-Malic acid salt of sunitinib (3 g) was dissolved in water (300 ml) at 40°C. The solution was filtered, cooled to 20° to 25°C, and charged to a spray dryer (BUCHI mini spray dryer B-290) at feed pump RPM of 7. The following parameters were controlled in the spray drying process:
Nozzle Diameter: 0.7 mm
Carrier gas: Nitrogen at 2.0 to 2.5 kg/cm2
Air inlet temperature: 130°C
Outlet temperature: 60°C
Aspiration: 70 %
Type of atomizer: Co current flow (also known as to fluid pressure nozzle) The solvent was evaporated at a temperature of about 60°C to about 65°C through spray drying. The solid so obtained was collected from the spray dryer to obtain the title compound having an XRPD pattern as depicted in Figure 1 initially and an XRPD pattern as depicted in Figure 2 after storage at 20°C to 25°C for 24 days.
Yield: 1.5 g
Moisture content by KF: 4.48% (initial)
Moisture content by KF: 5.52% (after storage at 20°C to 25°C for 60 days)
Claims
1. A stable crystalline Form II of L-malic acid salt of sunitinib.
2. A stable crystalline Form II of L-malic acid salt of sunitinib according to claim 1, wherein the stable crystalline Form II of L-malic acid salt does not convert into any other solid form on storage of about 20 days or more.
3. A stable crystalline Form Π of L-malic acid salt of sunitinib according to claim 1, wherein the stable crystalline Form II of L-malic acid salt absorbs moisture to a leve of not more than about 2%.
4. A process for the preparation of crystalline Form II of L-malic acid salt of sunitinib, wherein the process comprises:
a) charging a solution of L-malic acid salt of sunitinib in a solvent to a spray dryer;
b) removing the solvent from the solution obtained in step a) by spray drying; and c) collecting crystalline Form Π of L-malic acid salt of sunitinib from the spray dryer.
5. A process according to claim 4, wherein the solvent is water, an alkanol, or a mixture thereof.
6. A process according to claim 5, wherein the alkanol is methanol.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/510,986 US8916716B2 (en) | 2009-11-19 | 2010-11-19 | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib |
EP10801462.2A EP2501694A1 (en) | 2009-11-19 | 2010-11-19 | Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2386DE2009 | 2009-11-19 | ||
IN2386/DEL/2009 | 2009-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011061613A1 true WO2011061613A1 (en) | 2011-05-26 |
Family
ID=43531044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/002967 WO2011061613A1 (en) | 2009-11-19 | 2010-11-19 | Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib |
Country Status (3)
Country | Link |
---|---|
US (1) | US8916716B2 (en) |
EP (1) | EP2501694A1 (en) |
WO (1) | WO2011061613A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015056247A1 (en) | 2013-10-18 | 2015-04-23 | Ranbaxy Laboratories Limited | Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation |
WO2015056250A1 (en) | 2013-10-18 | 2015-04-23 | Ranbaxy Laboratories Limited | An ascorbic acid salt of sunitinib |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2828251B1 (en) * | 2012-03-23 | 2018-10-31 | Laurus Labs Limited | An improved process for the preparation of sunitinib and its acid addition salts thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030069298A1 (en) | 2001-08-15 | 2003-04-10 | Pharmacia & Upjohn Company | Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof |
US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2004012776A1 (en) | 2002-08-01 | 2004-02-12 | Pharmacia Italia S.P.A. | Isotopically labelled indolinone derivatives and process for their preparation |
WO2009067686A2 (en) | 2007-11-21 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof |
WO2009104021A2 (en) | 2008-02-21 | 2009-08-27 | Generics [Uk] Limited | Novel polymorphs and processes for their preparation |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
WO2010076805A2 (en) * | 2009-01-02 | 2010-07-08 | Hetero Research Foundation | Novel polymorphs of sunitinib malate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011033472A1 (en) * | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Salts of sunitinib |
WO2011092664A1 (en) * | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Crystalline forms of l-malic acid salt of sunitinib |
CA2792039A1 (en) * | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
-
2010
- 2010-11-19 US US13/510,986 patent/US8916716B2/en not_active Expired - Fee Related
- 2010-11-19 EP EP10801462.2A patent/EP2501694A1/en not_active Ceased
- 2010-11-19 WO PCT/IB2010/002967 patent/WO2011061613A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US7125905B2 (en) | 2000-02-15 | 2006-10-24 | Agouron Pharmaceuticals, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US20030069298A1 (en) | 2001-08-15 | 2003-04-10 | Pharmacia & Upjohn Company | Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof |
US20070191458A1 (en) | 2001-08-15 | 2007-08-16 | Pharmacia & Upjohn Company | Crystals Including a Malic Acid Salt of a 3-Pyrrole Substituted 2-Indolinone, and Compositions Thereof |
WO2004012776A1 (en) | 2002-08-01 | 2004-02-12 | Pharmacia Italia S.P.A. | Isotopically labelled indolinone derivatives and process for their preparation |
WO2009067686A2 (en) | 2007-11-21 | 2009-05-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof |
WO2009104021A2 (en) | 2008-02-21 | 2009-08-27 | Generics [Uk] Limited | Novel polymorphs and processes for their preparation |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
WO2010076805A2 (en) * | 2009-01-02 | 2010-07-08 | Hetero Research Foundation | Novel polymorphs of sunitinib malate |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015056247A1 (en) | 2013-10-18 | 2015-04-23 | Ranbaxy Laboratories Limited | Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation |
WO2015056250A1 (en) | 2013-10-18 | 2015-04-23 | Ranbaxy Laboratories Limited | An ascorbic acid salt of sunitinib |
US9278955B2 (en) | 2013-10-18 | 2016-03-08 | Sun Pharmaceutical Industries Limited | Ascorbic acid salt of sunitinib |
US9604968B2 (en) | 2013-10-18 | 2017-03-28 | Sun Pharmaceutical Industries Limited | Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation |
Also Published As
Publication number | Publication date |
---|---|
US8916716B2 (en) | 2014-12-23 |
EP2501694A1 (en) | 2012-09-26 |
US20130197242A1 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4048499A (en) | Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same | |
EP2247585A1 (en) | Crystal forms of n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation | |
US8916716B2 (en) | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib | |
KR100878455B1 (en) | Stable anhydrous crystalline docetaxel and method for the preparation therof | |
EP2342195B1 (en) | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt | |
WO2010076805A2 (en) | Novel polymorphs of sunitinib malate | |
JP2023504912A (en) | Crystal forms of 7H-benzo[7]annulene-2-carboxylic acid derivatives | |
WO2011033472A1 (en) | Salts of sunitinib | |
US20130210885A1 (en) | Crystalline forms of l-malic acid salt of sunitinib | |
EP3611160A1 (en) | Ammonium carboxylate compound, crystal form and amorphous substance thereof, and preparation method therefor | |
WO2016075588A1 (en) | Stable amorphous daclatasvir dihydrochloride | |
CN102241671A (en) | Precursor phase and use thereof for preparing the magnesium tetrahydrate salt of an omeprazole enantiomer | |
US9260380B2 (en) | Preparation of organic compounds for enhanced reactivity | |
WO2015056247A1 (en) | Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation | |
EP2499133A2 (en) | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib | |
JP2010132561A (en) | New type a crystal of cibenzoline succinate and method for producing the same | |
CN112961107B (en) | Luo Shasi his crystal form and preparation method thereof | |
EP2542550A1 (en) | Process for the direct preparation of malic acid salt of sunitinib | |
AU2022315418A1 (en) | Crystal form of compound represented by formula i, and preparation therefor and application thereof | |
WO2019155922A1 (en) | Method for producing azilsartan a-form crystal | |
WO2020092395A1 (en) | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE | |
JP2010077070A (en) | Method for purifying imidazole derivative | |
WO2018015847A1 (en) | Process for preparation of daclatasvir and salts | |
WO2008104956A2 (en) | Process for the preparation of amorphous cabergoline | |
CA2838585A1 (en) | An ascorbic acid salt of sunitinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10801462 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010801462 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5424/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13510986 Country of ref document: US |